A sample detection method and a blood analyzer

Abstract

This application discloses a sample detection method and a blood analyzer, which includes a control module and a testing module. The testing module is used to detect the sample to obtain sample information, including agglutination image information and / or parameter information. The control module is used to determine whether the sample is an agglutinated sample based on the sample information, and to obtain the detection result of the sample based on the determination result. The blood analyzer of this application can detect the sample through the testing module to obtain sample information, and the control module can make anomaly judgments on the sample based on the sample information, eliminating the need for manual agglutination sample identification, reducing labor costs, and improving the analysis efficiency of the blood analyzer.

Description

Technical Field

[0001] This application relates to the field of blood analysis technology, and in particular to a sample testing method and a blood analyzer. Background Technology

[0002] A blood analyzer is an instrument used to detect parameters such as the number, volume, and proportion of blood cells (red blood cells, white blood cells, platelets, and hemoglobin) in the blood. With technological advancements and scientific development, the functions of blood analyzers have been continuously expanded, their performance improved, and their level of automation increased, leading to their widespread application in blood analysis.

[0003] In blood cell analysis, blood cells are typically uniformly distributed in the blood sample. However, when there is an increase in agglutinin levels or the sample temperature is too low, the uniformly suspended blood cells can clump together due to charge imbalance, causing blood cell agglutination. This leads to blood cell parameters deviating from actual values ​​and affects the accuracy of the blood analyzer's measurement results. Existing sample detection methods require manual identification of agglutinated samples, which is cumbersome, costly, and hinders the improvement of the blood analyzer's analytical efficiency. Summary of the Invention

[0004] To address the aforementioned technical problems, this application provides a sample testing method and a blood analyzer.

[0005] To address the aforementioned problems, this application provides a sample detection method applied to a blood analyzer, comprising: a control module controlling a testing module to detect a sample to obtain sample information, the sample information including agglutination image information and / or parameter information; the control module determining whether the sample is an agglutinated sample based on the sample information; and the control module obtaining the detection result of the sample based on the determination result.

[0006] To address the aforementioned problems, this application provides a blood analyzer, including a control module and a testing module; the testing module is used to test the sample to obtain sample information; the control module is used to determine whether the sample is an agglutinated sample based on the sample information, and to obtain the test result of the sample based on the determination result.

[0007] This application provides a sample detection method and a blood analyzer, which includes a control module and a testing module. The testing module is used to detect the sample to obtain sample information, including agglutination image information and / or parameter information. The control module is used to determine whether the sample is an agglutinated sample based on the sample information, and to obtain the detection result of the sample based on the determination result. The blood analyzer of this application can detect the sample through the testing module to obtain sample information, and the control module can make anomaly judgments on the sample based on the sample information, eliminating the need for manual agglutination sample identification, reducing labor costs, and improving the analysis efficiency of the blood analyzer. Attached Figure Description

[0008] To more clearly illustrate the technical solutions in the embodiments of this application, the accompanying drawings used in the description of the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of this application. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort. Wherein:

[0009] Figure 1 This is a schematic diagram of the structure of the first embodiment of the blood analyzer provided in this application;

[0010] Figure 2 This is a schematic diagram of the structure of the second embodiment of the blood analyzer provided in this application;

[0011] Figure 3 This is a flowchart illustrating the first embodiment of the sample processing method provided in this application;

[0012] Figure 4 This is a flowchart illustrating the second embodiment of the sample processing method provided in this application;

[0013] Figure 5 This is a flowchart illustrating the third embodiment of the sample processing method provided in this application;

[0014] Figure 6 This is a flowchart illustrating the fourth embodiment of the sample processing method provided in this application;

[0015] Figure 7 This is a flowchart illustrating the fifth embodiment of the sample processing method provided in this application;

[0016] Figure 8 This is a flowchart illustrating the first embodiment of the sample detection method provided in this application;

[0017] Figure 9 This is a flowchart illustrating the second embodiment of the sample detection method provided in this application;

[0018] Figure 10 This is a schematic diagram of the third embodiment of the blood analyzer provided in this application;

[0019] Figure 11 This is a schematic diagram of an embodiment of the computer-readable storage medium provided in this application. Detailed Implementation

[0020] The technical solutions of the embodiments of this application will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of this application, and not all embodiments. Based on the embodiments of this application, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of this application.

[0021] It should be noted that if the embodiments of this application involve directional indicators (such as up, down, left, right, front, back, etc.), the directional indicators are only used to explain the relative positional relationship and movement of the components in a certain specific posture (as shown in the figure). If the specific posture changes, the directional indicators will also change accordingly.

[0022] Furthermore, if the embodiments of this application involve descriptions such as "first" or "second," these descriptions are for descriptive purposes only and should not be construed as indicating or implying their relative importance or implicitly specifying the number of technical features indicated. Therefore, features defined with "first" or "second" may explicitly or implicitly include at least one of those features. Additionally, the technical solutions of various embodiments can be combined with each other, but this must be based on the ability of those skilled in the art to implement them. If the combination of technical solutions is contradictory or impossible to implement, it should be considered that such a combination of technical solutions does not exist and is not within the scope of protection claimed in this application.

[0023] In view of this, this application proposes a sample processing method applicable to a blood analyzer used to count cells in a blood sample to obtain count-related parameters. This sample processing method is used to process agglutinated samples from the blood analyzer to obtain detection results for the agglutinated samples. Specifically, the sample processing method of this application embodiment is used to determine whether a sample from the blood analyzer is an agglutinated sample and to perform deagglutination processing on the agglutinated sample to obtain detection results for the agglutinated sample.

[0024] Please see Figure 1 , Figure 1 This is a schematic diagram of the structure of the first embodiment of the blood analyzer provided in this application. Figure 1As shown, the blood analyzer includes a control module 10 and a test module 30. The test module 30 is used to test the sample to obtain the sample information. The control module 10 is used to determine whether the sample is an agglutinated sample based on the sample information, and then obtain the test result of the sample based on the determination result.

[0025] Specifically, in one embodiment, the sample information includes agglutination image information or parameter information. The test module 30 includes a sample testing component and an image detection component. The sample testing component is used to perform a sample testing process on the sample. The sample testing process is related to the sample object; for example, when the sample is a red blood cell sample, the sample testing process is a red blood cell testing process, and when the sample is a platelet sample, the sample testing process is a platelet testing process. After the sample testing component performs the testing process on the sample, the test module 30 obtains the parameter information of the sample, so that the control module 10 determines whether the sample is an agglutination sample based on the parameter information. The image detection component is used to perform image detection on the sample; for example, the image detection component may include a camera.

[0026] In another embodiment, the sample information includes agglutination image information and parameter information. The control module 10 is used to determine that the sample is an agglutinated sample when neither the agglutination image information nor the parameter information meets the first preset condition. Alternatively, the control module 10 is used to obtain the reliability of the sample judgment result based on the agglutination image information and the parameter information. For example, the control module 10 performs a first judgment on the agglutinated sample using either the parameter information or the agglutination image information. If the reliability of the first judgment result is low (e.g., the parameter information deviates excessively from the normal threshold, the agglutination image is unclear, or the agglutination image contains unidentifiable foreign objects), the control module 10 performs a second judgment on the agglutinated sample using the other of the parameter information and the agglutination image information, and uses the result of the second judgment as the final judgment result.

[0027] In this embodiment, the blood analyzer can test the sample through the test module 30 to obtain sample information, and the control module 10 can make anomaly judgment on the sample based on the sample information. There is no need for manual identification of agglutinated samples, which reduces labor costs and improves the analysis efficiency of the blood analyzer.

[0028] Optionally, the blood analyzer also includes a deagglutination processing module 20. When the control module 10 determines that the sample is an agglutinated sample, the deagglutination processing module 20 is used to perform deagglutination processing on the agglutinated sample. The testing module 30 is used to test the processed sample to obtain the test information of the sample. The control module 10 is also used to generate the test results of the sample based on the test information.

[0029] Specifically, the deagglutination process varies depending on the sample. For example, when the agglutinated sample is a red blood cell agglutination sample or a white blood cell agglutination sample, the deagglutination process is performed to disperse the agglutinated red blood cells or white blood cells before measurement. When the agglutinated sample is a PLT (platelet) agglutination sample, the deagglutination process involves test channel conversion, converting the test channel to the PLT-F channel for testing. The forward scattered light and lateral fluorescence of PLT are obtained by semiconductor laser flow cytometry to form a two-dimensional scatter plot, thereby enabling more accurate counting of PLT.

[0030] The control module 10 is connected to the deagglutination processing module 20 and the testing module 30. The control module 10 is used to control the abnormal handling process of the deagglutination processing module 20 and the testing process of the testing module 30. For example, when the sample is determined to be an agglutinated sample based on the sample information, the control module 10 controls the deagglutination processing module 20 to perform deagglutination processing on the agglutinated sample. The control module 10 is also used to control the testing module 30 to execute the testing process of the agglutinated sample after the deagglutination processing of the agglutinated sample is completed, so as to obtain the testing information of the agglutinated sample. The control module 10 generates the detection result of the agglutinated sample based on the testing information, so that the blood analyzer can automatically perform deagglutination processing on the agglutinated sample when the sample is an agglutinated sample, without the need for manual processing of the agglutinated sample, reducing the sample processing cost and improving the analysis efficiency of the blood analyzer.

[0031] Optionally, when the control module 10 determines that a sample is an agglutinated sample, the control module 10 is used to obtain the degree of agglutination of the sample based on the sample information, and the deagglutination processing module 20 is used to perform deagglutination processing on the sample based on the degree of agglutination. For example, the deagglutination processing module 20 has multiple preset deagglutination processing schemes, and the control module 10 classifies the degree of agglutination of the sample according to the preset deagglutination processing schemes, so that the control module 10 can obtain the degree of agglutination based on the sample information.

[0032] Further, the degree of agglutination is used to indicate the agglutination titer of the agglutinated sample. In one embodiment, the degree of agglutination includes a first degree of agglutination and a second degree of agglutination, wherein the agglutination titer of the second degree of agglutination is greater than that of the first degree of agglutination. The deagglutination processing module 20 is used to incubate the agglutinated sample of the first degree of agglutination, and also to incubate and dilute the agglutinated sample of the second degree of agglutination. In another embodiment, the degree of agglutination includes a first degree of agglutination, a second degree of agglutination, and a third degree of agglutination, wherein the agglutination titers of the first degree of agglutination, the second degree of agglutination, and the third degree of agglutination increase sequentially. The deagglutination processing module 20 is used to incubate the agglutinated sample of the first degree of agglutination, and also to incubate and dilute the agglutinated sample of the second degree of agglutination by a first preset factor, and to incubate and dilute the abnormal sample of the third degree of agglutination by a second preset factor, wherein the second preset factor is greater than the first preset factor.

[0033] In other embodiments, when the agglomerated sample is at different agglomeration levels, the deagglomeration processing module 20 can also select at least one of incubation treatment, dilution treatment, and mixing treatment to combine deagglomeration schemes according to the agglomeration level, so as to perform deagglomeration treatment on the agglomerated sample. For example, when the agglomerated sample is at different agglomeration levels, the deagglomeration scheme can be a combination of incubation treatment with different incubation durations, dilution treatment with different dilution ratios, and mixing treatment with different mixing strengths, or the deagglomeration scheme can be a combination of incubation treatment, dilution treatment, and mixing treatment, without specific limitations.

[0034] Optionally, the sample information includes, but is not limited to, the sample's red blood cell parameters, platelet parameters, white blood cell parameters, histogram information, statistical scatter plot information, and agglutination image information.

[0035] Optionally, the blood analyzer is provided with at least one incubation position 230, which is used to place agglutinated samples so that the agglutinated samples are incubated in the incubation position 230 and deagglutinated at a first preset temperature. The deagglutination processing module 20 is used to incubate the agglutinated samples located in the incubation position 230.

[0036] Specifically, the deagglutination processing module 20 includes a heating component and a transfer component 210. The heating component is located at the incubation position 230 and is used to heat the incubation position 230 to maintain it at a first preset temperature. The transfer component 210 is used to move the agglutinated sample to the incubation position 230. The heating method of the heating component can be solid heat conduction, whereby the test tube containing the agglutinated sample is directly heated by heating a solid to maintain the incubation position 230 at the first preset temperature. Other heating methods include water bath heating, air bath heating, etc., which are not specifically limited here.

[0037] The first preset temperature is in the range of 35℃ to 43℃, for example, the first preset temperature can be 35℃, 36℃, 37℃, 38℃, 39℃, 40℃, 41℃, 42℃ or 43℃; the incubation time is in the range of 5 minutes to 60 minutes, for example, the incubation time can be 5 minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 35 minutes, 40 minutes, 45 minutes, 50 minutes, 55 minutes or 60 minutes.

[0038] When the incubation position 230 is maintained at a first preset temperature of 35℃ to 43℃, which is close to the body temperature, the agglutinated blood cells in the agglutinated sample can undergo deagglutination at the first preset temperature. The longer the incubation time, the better the deagglutination effect, but the lower the sample analysis efficiency. Therefore, the incubation time can be controlled according to the degree of agglutination of the agglutinated sample and sample analysis scheduling.

[0039] Optionally, the deagglomeration processing module 20 includes a dilution component for diluting the agglomerated sample by a preset factor.

[0040] The preset multiple can be in the range of 60 to 1024. For example, the first preset multiple can be 60, 120, 250, 500 or 1000. Or, the first preset multiple can be 64, 128, 256, 512 or 1024. The first preset multiple can be selected according to the degree of agglutination of the agglutinated sample, and no specific limitation is made here.

[0041] The temperature of the diluent is in the range of 33℃ to 38℃. Since the agglutinated sample is incubated in the range of 35℃ to 43℃, the control module 10 can heat the diluent before adding it to the dilution component to keep its temperature in the range of 33℃ to 38℃, which is close to the temperature of the agglutinated sample after incubation, so as to enhance the dilution and deagglomeration effect.

[0042] The dilution assembly includes a dilution pool 220 and a diluent tank. The dilution pool 220 is used to contain the agglutinated sample and the diluent, so that the diluent and the agglutinated sample react and the agglutinated sample is diluted to a preset multiple. The diluent tank is used to store the diluent.

[0043] In one embodiment, the dilution pool 220 is a sample preparation pool for a blood analyzer. The dilution pool 220 also contains the sample and diluent for pre-dilution of the sample. The testing module 30 is used to test the pre-diluted sample to obtain sample information. Before testing, the blood analyzer sample needs to undergo pretreatment such as mixing and pre-dilution. Diluents and testing reagents are added to the sample preparation pool to obtain the sample to be tested. The testing module 30 then tests the sample to obtain sample information. Specifically, the sample to be tested obtained in the sample preparation pool can be used for at least one of the following: red blood cell detection, white blood cell detection, platelet detection, and hemoglobin detection.

[0044] In other embodiments, the dilution pool 220 of the dilution component is only used to dilute the agglutinated sample, that is, the dilution pool 220 is used to dilute the agglutinated sample. The test module 30 also includes a sample preparation pool, which is used to prepare the agglutinated sample or the sample before testing.

[0045] Optionally, the blood analyzer includes a sample dispensing module 40, which includes a sample needle 430 and a power unit.

[0046] In one embodiment, the dilution pool 220 is the sample preparation pool of a blood analyzer. A power unit is connected to the sample preparation pool and the diluent tank. The power unit is used to add reagents such as diluent and detection reagents to the sample preparation pool. For example, the power unit includes, but is not limited to, a metering pump. The sample needle 430 is used to transfer agglutinated samples to add them to the dilution pool 220. The power unit is used to add a quantitative amount of diluent to the dilution pool 220. Since the power unit adds the diluent quantitatively, the volume of agglutinated sample transferred by the sample needle 430 can be adjusted to achieve a preset dilution factor, allowing the dilution unit to adjust the dilution factor.

[0047] In another embodiment, the sample needle 430 is used to add diluent and sample to the dilution pool 220 to dilute the agglutinated sample in the dilution pool 220 by a preset factor. In this case, since the sample needle 430 can select the volume of diluent and sample to be delivered, the dilution factor of the agglutinated sample can be adjusted by adjusting the volume of the sample and diluent.

[0048] Optionally, please see Figure 2 , Figure 2 This is a schematic diagram of the second embodiment of the blood analyzer provided in this application. Figure 2 As shown, the sample loading module 40 is used to obtain the agglutinated sample after deagglutination treatment and perform a sample preparation process on the agglutinated sample so that the test module 30 can detect the agglutinated sample.

[0049] Specifically, after the blood analyzer receives a sample, the transport component 210 transfers the sample to the sample loading module 40. The sample loading module 40 is equipped with a suction position 440. The transport component 210 moves the sample to the suction position 440 so that the sample loading module 40 can perform a sample preparation process on the agglutinated sample at the suction position 440, so that the test module 30 can detect the sample and obtain the sample information. After the detection is completed, the control module 10 determines whether the sample is an agglutinated sample based on the sample information. If the sample is determined to be an agglutinated sample, the control module 10 controls the deagglutination processing module 20 to perform deagglutination processing on the agglutinated sample. After the deagglutination processing is completed, the transport component 210 transfers the processed agglutinated sample to the sample loading module 40. The sample loading module 40 performs a sample preparation process on the agglutinated sample so that the test module 30 can detect the agglutinated sample and obtain the test information of the agglutinated sample.

[0050] Optionally, the sample addition module 40 includes a first mixer 410, which is used to mix the agglutinated sample after deagglutination treatment in a first mixing mode; the first mixer 410 is also used to mix the sample in a second mixing mode so that the test module 30 can detect the mixed sample and obtain sample information; wherein the mixing intensity of the first mixing mode is less than the mixing intensity of the second mixing mode.

[0051] The sample preparation process of the sample loading module 40 includes at least a pre-test mixing process. The sample loading module 40 mixes the agglutinated sample or the sample through the first mixer 410. Specifically, after the blood analyzer receives the sample, the first mixer 410 acquires the sample and mixes it in a second mixing mode so that the test module 30 can perform the detection process on the mixed sample and acquire sample information. When the sample is an agglutinated sample, the control module 10 controls the deagglutination processing module 20 to deagglutinate the agglutinated sample. Then, the transport component 210 transfers the deagglutinated sample to the first mixer 410 so that the first mixer 410 mixes the agglutinated sample in a first mixing mode. Since the agglutinated sample has undergone incubation and / or dilution treatment by the deagglutination processing module 20, in order to avoid damage to the blood cells of the processed agglutinated sample during the mixing process, the first mixer 410 uses a first mixing mode with a lower mixing intensity to mix the agglutinated sample, ensuring the reliability of the agglutinated sample.

[0052] In one embodiment, the mixing method of the first mixer 410 is gripper mixing. The first mixer 410 grabs the sample or agglomerated sample by gripper and mixes the sample or agglomerated sample according to a preset frequency and preset posture. The frequency used in the first mixing mode is lower than the frequency of the second mixing mode.

[0053] Optionally, the blood analyzer includes a sample injection module for receiving samples and acquiring sample information, and a control module 10 for determining, based on the sample information, whether the sample is an agglutinated sample after deagglutination treatment, so that the sample dispensing module 40 can acquire the agglutinated sample.

[0054] The first mixer 410 is also used to acquire samples from the injection module. Specifically, after the injection module receives the sample, the first mixer 410 grabs the sample from the injection module and mixes the sample according to a preset frequency and preset posture. The transfer assembly 210 includes a transfer position 211 for carrying the sample tube. The transfer assembly 210 is used to move the sample located at the transfer position 211 from the side near the first mixer 410 to the suction position 440. After the first mixer 410 mixes the sample, it places the mixed sample on the transfer position 211 so that the transfer assembly 210 moves the sample to the suction position 440. The sample loading module 40 performs a sample preparation process on the sample at the suction position 440 so that the testing module 30 can detect the sample and obtain sample information. The control module 10 determines whether the sample is an agglutinated sample based on the sample information.

[0055] In this embodiment, since the incubation process takes a relatively long time (ranging from 5 to 60 minutes), when the control module 10 determines that the sample is an agglutinated sample, it acquires the usage status of the incubation position 230. If all incubation positions 230 on the blood analyzer are in the incubation state (i.e., the agglutinated sample cannot be moved to the incubation position 230), the blood analyzer can remove the agglutinated sample from the machine, mark the corresponding identification code, and issue a warning message to prompt the user to perform manual incubation on the agglutinated sample. After the user performs manual incubation on the agglutinated sample, the sample is placed in the sample injection module. The sample injection module receives the sample according to the set injection procedure and identifies the sample's identification code. When the sample's identification code includes the mark, the control module 10 determines that the sample is an incubated agglutinated sample and controls other modules to perform subsequent operations on the incubated agglutinated sample. For example, the control module 10 can control the deagglutination processing module 20 to dilute the agglutinated sample after incubation, or the control module 10 can control the testing module 30 to test the agglutinated sample after incubation.

[0056] Optionally, in one embodiment, the deagglomeration processing module 20 includes an incubation component, which is provided with at least one first incubation position 230. The incubation component is used to incubate the agglomerated sample located at the first incubation position 230 so that the agglomerated sample deagglomerates at a first preset temperature.

[0057] In another embodiment, the sample addition module 40 includes a second mixer 420, which is provided with a second incubation position 230. The second mixer 420 is used to incubate the agglomerated sample located in the second incubation position 230 so that the agglomerated sample deagglomerates at a first preset temperature.

[0058] Specifically, depending on the blood collection method, the sample tubes adapted to the blood analyzer typically include micro-blood tubes and whole blood tubes. After the sample injection module receives the whole blood tube, the first mixer 410 grabs the whole blood tube with a gripper and performs a mixing operation on the whole blood tube in the second mixing mode. Since the micro-blood content is small and the micro-blood tube has a double-layer structure, the first mixer 410 cannot mix the micro-blood tube. Therefore, the blood analyzer is usually equipped with a second mixer 420. The second mixer 420 is used to perform a mixing operation on the micro-blood tube. For example, the second mixer 420 can periodically bump the micro-blood tube to bounce and mix the micro-blood sample.

[0059] Since existing blood analyzers typically have multiple testing items, the number of micro-blood tubes in the blood analyzer is limited due to the number of testing items, making the second mixer 420 usually idle. Therefore, in this embodiment, the second mixer 420 is reused by using the micro-blood mixing position of the second mixer 420 to incubate the agglutinated sample. This eliminates the need for a separate incubation position 230 or reduces the number of incubation positions 230, which helps to simplify the structure of the blood analyzer and reduce its size.

[0060] Understandably, the incubation treatment of agglutinated samples can be performed at the first mixing position and / or the second mixing position. That is, the blood analyzer can have only one first mixing position, which is used only for the incubation process of agglutinated samples; or, the blood analyzer can also reuse the second mixing position of the second mixer 420 to incubate agglutinated samples without setting the first incubation position 230, so as to simplify the spatial structure of the blood analyzer and reduce its volume; or, when there are many agglutinated samples, the blood analyzer can also set at least one first mixing position and a second mixing position at the same time, so that the deagglutination processing module 20 can perform incubation treatment of multiple agglutinated samples at the same time, thereby improving the efficiency of abnormal processing.

[0061] The second mixer 420 is used to mix a small amount of blood sample in the third mixing mode and to mix the agglutinated sample located in the second incubation position 230 in the fourth mixing mode. When the blood analyzer incubates the agglutinated sample using the second mixer 420, to improve the deagglutination rate, the control module 10 can control the second mixer 420 to mix the incubated agglutinated sample during the incubation process. To prevent the blood cells in the agglutinated sample from rupturing during incubation, the mixing intensity of the fourth mixing mode is lower than that of the third mixing mode, ensuring the accuracy of the sample analysis results.

[0062] The mixing intensity of the second mixer 420 can be reflected in the mixing amplitude, mixing intensity, and motor power used by the second mixer 420, etc., without specific limitations here.

[0063] Optionally, the first mixer 410 is used to grab the agglutinated sample from the first incubation position 230, and / or the first mixer 410 is used to grab the agglutinated sample from the second incubation position 230 to move the agglutinated sample to the transfer component 210, so that the transfer component 210 transfers the incubated agglutinated sample to other modules or components.

[0064] Specifically, to facilitate the grasping of agglutinated samples, the first incubation position 230 is a point on the grasping trajectory of the first mixer 410, and / or, to facilitate the sample loading module 40 to acquire agglutinated samples for performing sample preparation procedures on the agglutinated samples, the first incubation position 230 is a point on the movement trajectory of the sample loading module 40.

[0065] Optionally, the test module 30 includes an image detection component for performing image detection on the sample to obtain agglutination image information of the sample. Specifically, when agglutination occurs in red blood cell or white blood cell samples, the user can visually distinguish between agglutinated samples. The image detection component is used to obtain agglutination image information of the sample so that the control module 10 can determine whether the sample is an agglutinated sample based on the agglutination image information. The image detection component includes, but is not limited to, a camera.

[0066] Furthermore, after obtaining agglomerated image information through the image detection component, the control module 10 determines the sample as an agglomerated sample when the matching degree between the agglomerated image information and the preset feature information is greater than a preset threshold.

[0067] The preset feature information includes sample layering features and / or sample surface features. The control module 10 is used to match the sample layering features and / or sample surface features with agglutination image information to obtain the matching degree. Specifically, in one embodiment, when red blood cell or white blood cell samples agglutinate, layering occurs on the sample surface. The control module 10 can determine whether the sample is an agglutinated sample by matching the sample layering features with the agglutination image information. For example, when layering occurs on the sample surface, the control module 10 can obtain color value change information or grayscale change information in the extension direction of the sample tube based on the agglutination image information, so as to obtain the matching degree of the agglutinated sample based on the color value change information or grayscale change information.

[0068] In another embodiment, when red blood cell or white blood cell samples agglutinate, sand-like or flocculent substances appear on the sample surface. The control module 10 can determine whether the sample is an agglutinated sample by acquiring the sample surface features and matching the sample surface features with the agglutination image information. For example, when sand-like or flocculent substances appear on the sample surface, the control module 10 can identify the sand-like or flocculent features of the agglutination image information to obtain the matching degree between the sample surface features and the agglutination image information, so as to determine whether the sample is stratified based on the matching degree.

[0069] In other embodiments, the matching degree can be obtained by combining the two embodiments described above. For example, agglomeration image information can be identified at the same time, and the agglomeration samples can be judged based on the first matching degree of the sample layering features and the agglomeration image information, and the second matching degree of the sample surface features and the agglomeration image information. No specific limitation is made here.

[0070] Please see Figure 3 , Figure 3 This is a flowchart illustrating the first embodiment of the sample processing method provided in this application. Figure 3 As shown, the blood analyzer of this embodiment may include a testing module 30, a control module 10, and a deagglutination processing module 20. The control module 10 is connected to the testing module 30 and the deagglutination processing module 20, and is used to control the execution process of the testing module 30 and the deagglutination processing module 20. The sample processing method of this embodiment includes the following steps:

[0071] Step S11: The control module 10 acquires the sample information of the sample and determines whether the sample is an agglutinated sample based on the sample information.

[0072] In an optional implementation, before step S11, the sample processing method includes the following steps: the control module 10 controls the sample addition module 40 to receive the sample; the control module 10 controls the testing module 30 to test the sample to obtain sample information.

[0073] Depending on the specific tests performed, the blood analyzer may have multiple testing components. For example, the testing module 30 may include at least a first testing component and a second testing component. These components are used to perform different testing procedures on the sample. In one embodiment, the sample is fed into the blood analyzer. After either the first or second testing component tests the sample, sample information is obtained. The control module 10 then determines whether the sample is an agglutinated sample based on this information. For instance, the sample information may be blood cell parameter information or histogram information from a blood cell count test. When the testing module 30 performs sample testing using laser scattering and fluorescence staining methods, the sample information may also be a statistical scatter plot of various cell types.

[0074] In other embodiments, the test module 30 further includes an image detection component. Before the test module 30 detects the sample, the control module 10 controls the image detection component to perform image detection on the sample to obtain sample information and determine whether the sample is an agglutinated sample based on the sample information. Agglutinated samples include, but are not limited to, erythrocyte agglutination samples, leukocyte agglutination samples, platelet agglutination samples, and hemoglobin agglutination samples.

[0075] Step S12: When the sample is an agglutinated sample, the control module 10 controls the deagglutination processing module 20 to perform deagglutination processing on the agglutinated sample.

[0076] After acquiring sample information, the control module 10 determines whether the sample is an agglutinated sample based on the sample information. If the sample is a normal sample, the control module 10 moves the sample to the corresponding test module 30 for testing. If the sample is an agglutinated sample, the control module 10 controls the deagglutination processing module 20 to perform deagglutination processing on the agglutinated sample.

[0077] Step S13: Control module 10 controls test module 30 to test the processed agglutinated sample to obtain test information of the agglutinated sample.

[0078] After deagglomerating the agglomerated sample, the control module 10 controls the testing module 30 to test the processed agglomerated sample to obtain test information. Specifically, the control module 10 can control at least one of the first testing component and the second testing component to test the agglomerated sample. For example, the first testing component performs a single test to obtain sample information, and then controls the first testing component to perform a second test on the processed agglomerated sample to determine whether the deagglomeration of the processed agglomerated sample is effective based on the test information.

[0079] Step S14: The control module 10 generates the detection results of the agglutinated sample based on the test information.

[0080] The test information can be the parameter results of a blood cell count test; when the test module 30 tests samples using laser scattering and fluorescence staining methods, the test information can also be statistical scatter plots of various cell types, etc. The specific type of test information is related to the detection items of the test module 30, and is not specifically limited here. After acquiring the test information of the agglutinated sample, the control module 10 generates the detection results of the agglutinated sample based on the test information. The detection results can include the test information and the prompt information obtained by the control module 10 based on the test information. For example, the prompt information can include the deagglutination treatment plan for the agglutinated sample, the effectiveness of the deagglutination treatment, and related suggestions.

[0081] In this embodiment, the control module 10 determines whether a sample is an agglutinated sample based on its sample information. If the sample is an agglutinated sample, the control module 10 controls the deagglutination processing module 20 to perform deagglutination processing on the agglutinated sample, and controls the testing module 30 to test the processed agglutinated sample to obtain test information. The control module 10 generates the test result of the agglutinated sample based on the test information. This sample processing method can identify and handle anomalies in samples based on sample information, eliminating the need for manual processing of agglutinated samples, reducing sample processing costs, and improving the analytical efficiency of the blood analyzer.

[0082] Optionally, in one embodiment, step S12 includes the following steps: when the sample is an agglutinated sample, the control module 10 controls the deagglutination processing module 20 to move the agglutinated sample to the incubation position 230; the control module 10 controls the temperature of the incubation position 230 so that the agglutinated sample deagglutinates at a first preset temperature.

[0083] Specifically, blood cells can agglutinate due to factors such as low temperature and abnormal lectins, resulting in abnormal changes in blood cell volume. This causes false changes in red blood cell counts when the blood analyzer tests the sample, affecting the accuracy of the blood analyzer's detection. Therefore, when the control module 10 detects an agglutinated sample, it needs to perform deagglutination processing on the agglutinated sample to ensure the accuracy of the detection.

[0084] The control module 10 controls the deagglomeration processing module 20 to move the agglomerated sample to the incubation position 230. The control module 10 controls the temperature of the incubation position 230 to deagglomerate the agglomerated sample at a first preset temperature. The first preset temperature can be in the range of 35℃-43℃.

[0085] The control module 10 controls the deagglomeration processing module 20 to perform a preset time incubation on the agglomerated sample. After the incubation is completed, the control module 10 controls the testing module 30 to test the agglomerated sample. The test information of the agglomerated sample is used to determine whether the incubation treatment is effective in deagglomeration. If the incubation treatment is ineffective in deagglomeration, the control module 10 can output an alarm message. Alternatively, the control module 10 can control the deagglomeration processing module 20 to continue the deagglomeration treatment on the agglomerated sample.

[0086] In another embodiment, please refer to Figure 4 , Figure 4 This is a flowchart illustrating a second embodiment of the sample processing method provided in this application. Figure 4 As shown, in this embodiment, the deagglomeration processing module 20 includes a dilution component, which is used to dilute the agglomerated sample. Step S12 includes the following steps:

[0087] Step S21: When the sample is an agglutinated sample, the control module 10 controls the deagglutination processing module 20 to move the agglutinated sample to the incubation position 230.

[0088] When the sample is an agglutinated sample, the control module 10 controls the deagglutination processing module 20 to move the agglutinated sample to the incubation position 230 for incubation for a preset time.

[0089] Step S22: The control module 10 controls the temperature of the incubation position 230 so that the agglutinated sample deagglutinates at the first preset temperature.

[0090] The control module 10 controls the temperature of the incubation site 230 to deagglomerate the agglomerated sample at a first preset temperature. The first preset temperature is in the range of 35℃-43℃, for example, the first preset temperature can be 35℃, 36℃, 37℃, 38℃, 39℃, 40℃, 41℃, 42℃ or 43℃. The first preset temperature is close to the human body temperature to simulate the environment of blood samples in the human body and accelerate the deagglomeration rate of the agglomerated sample.

[0091] Step S23: Control module 10 controls sample addition module 40 to add the incubated agglutinated sample and diluent to the dilution component to dilute the agglutinated sample in the dilution component by a first preset factor.

[0092] Specifically, the blood analyzer also includes a sample loading module 40, which is connected to the control module 10. After the agglutinated sample has been incubated, the control module 10 controls the sample loading module 40 to add the incubated agglutinated sample to the dilution component and add diluent to the dilution component to dilute the agglutinated sample by a first preset factor. This increases the intercellular spacing of the diluted agglutinated sample, thereby deagglutinating the agglutinated blood cells. The first preset factor is in the range of 60 to 1024.

[0093] The order in which the sample addition module 40 adds the agglutinated sample and the diluent can be either adding the agglutinated sample first or adding the diluent first. The first preset dilution can be achieved by adjusting the amount of agglutinated sample added or adjusting the amount of diluent added. There are no specific restrictions on the order and amount of addition.

[0094] In the embodiments of this application, the sample processing method can incubate and / or dilute agglutinated samples to reduce the agglutination degree of the agglutinated samples, reduce the impact of agglutinated samples on detection parameters, and improve the analysis efficiency of the blood analyzer.

[0095] Optionally, before the control module 10 controls the sample addition module 40 to add the agglutinated sample and diluent, the control module 10 controls the dilution component to heat the diluent to a second preset temperature, which is in the range of 28°C to 38°C. After preheating, the temperature of the diluent is close to that of the agglutinated sample, so as to enhance the dilution and deagglomeration effect.

[0096] Furthermore, after the deagglomeration processing module 20 performs corresponding abnormal handling measures on the agglomerated sample, the control module 10 controls the testing module 30 to test the processed agglomerated sample to obtain the test information of the agglomerated sample and generate the corresponding test results based on the test information.

[0097] Specifically, in one embodiment, the deagglutination processing module 20 incubates the agglutinated sample to deagglutinate the agglutinated blood cells at a first preset temperature. At this time, the control module 10 controls the testing module 30 to test the incubated agglutinated sample to obtain first test information of the agglutinated sample. The first test information consists of test parameters of the agglutinated sample. For example, when the agglutinated sample is a red blood cell agglutination sample, the first test information may include at least one of mean corpuscular hemoglobin concentration (MCHC), mean corpuscular volume (MCV), hematocrit (HCT), red blood cell count (RBC), and mean corpuscular hemoglobin content (MCH). The control module 10 determines whether the agglutination titer of the incubated agglutinated sample is within a preset range based on the parameters of the first test information, thereby obtaining the detection result of the agglutinated sample.

[0098] For example, when the first test information includes the MCHC parameter, the agglutination titer of the agglutinated sample can be determined by whether the MCHC is greater than a first preset value. For example, the first preset value can be 360 ​​g / L or 380 g / L. When the MCHC is greater than 360 g / L or 380 g / L, the agglutination titer of the agglutinated sample is high, and blood cell agglutination occurs in the agglutinated sample. When the first test information includes the MCV parameter, the agglutination titer of the agglutinated sample can be determined by whether the MCV is high. When the first test information includes the HCT parameter, the agglutination titer of the agglutinated sample can be determined by whether the HCT is low. The agglutination titer of an agglutinated sample is determined as follows: When the first test information includes the RBC parameter, a high agglutination titer can be determined by judging whether the RBC is low; when the first test information includes the MCH parameter, a high agglutination titer can be determined by judging whether the MCH is high, for example, whether the MCH is greater than a second preset value, which could be 33 pg; when the first test information includes HGB and RBC parameters, the condition for determining a high agglutination titer is whether the first ratio of HGB to RBC is greater than a third preset value, for example, the third preset value could be 30. It is understood that the above-mentioned methods can be combined arbitrarily. For example, the agglutination titer of an agglutinated sample can be determined based on the first ratio of HGB to RBC, MCH, and MCHC, or it can be determined based on other parameters. No specific limitation is made here regarding the method of determining the agglutination titer of an agglutinated sample.

[0099] In another embodiment, the deagglutination processing module 20 incubates the agglutinated sample and then dilutes it. At this time, the control module 10 controls the testing module 30 to test the diluted agglutinated sample to obtain second test information. Similarly, when the agglutinated sample is a erythrocyte agglutination sample, the second test information may include at least one of mean corpuscular hemoglobin concentration (MCHC), mean corpuscular volume (MCV), hematocrit (HCT), red blood cell count (RBC), and mean corpuscular hemoglobin content (MCH). The control module 10 determines whether the agglutination titer of the diluted agglutinated sample is within a preset range based on the parameters of the second test information, thereby obtaining the detection result of the agglutinated sample.

[0100] In yet another implementation, please refer to Figure 5 , Figure 5 This is a flowchart illustrating the third embodiment of the sample processing method provided in this application. Figure 5 As shown, the deagglutination processing module 20 incubates the agglutinated sample to obtain the first test information of the agglutinated sample. Step S14 includes the following steps:

[0101] Step S31: In response to the first test information not meeting the first preset condition, the control module 10 uses the first test information as the detection result.

[0102] Specifically, the first test information is the test parameters of the incubated agglutinated sample. The control module 10 uses the first test information to determine whether the agglutination titer of the incubated agglutinated sample is too high. The first preset condition is used to determine the agglutination state of the agglutinated sample. When the first test information meets the first preset condition, the incubated agglutinated sample still exhibits blood cell agglutination, and the agglutination titer of the agglutinated sample is high. When the first test information does not meet the first preset condition, the agglutination titer of the incubated agglutinated sample is low, the degree of blood cell agglutination is low, or the blood cells do not agglutinate. In this case, the first test information is used as the detection result.

[0103] The first preset condition is related to the parameters of the first test information. The first preset condition may include one or more of the above-mentioned methods for judging the agglutination titer of the incubated agglutinated sample based on the first test information. Here, the first preset condition is not specifically limited. When the first test information meets the first preset condition, the agglutination titer of the incubated agglutinated sample is low, and the control module 10 uses the first test information as the detection result of the agglutinated sample.

[0104] Step S32: In response to the first test information not meeting the first preset condition, the control module 10 controls the deagglutination processing module 20 to dilute the agglutinated sample after incubation.

[0105] When the first test information does not meet the first preset condition, it indicates that the agglutination titer of the incubated agglutinated sample is high. The control module 10 controls the deagglutination processing module 20 to dilute the incubated agglutinated sample. The specific dilution method is similar to step S23 and will not be described again here. After the dilution process is completed, the control module 10 controls the test module 30 to test the diluted agglutinated sample to obtain the second test information, which is then used as the test result of the agglutinated sample.

[0106] In this embodiment, the control module 10 selects whether to dilute the incubated agglutinated sample based on the first test information, so as to reduce the time spent on abnormal processing and improve the analysis efficiency of the blood analyzer.

[0107] Optionally, in one embodiment, when the deagglutination processing module 20 dilutes the agglutinated sample, the dilution factor is in the range of 60 to 1024. The deagglutination processing module 20 can obtain agglutination type information of the agglutinated sample by diluting the agglutinated sample at different dilution factors. The control module 10 outputs the test results based on the test information and agglutination type information, allowing the user to view the aggregation type, deagglutination scheme, and deagglutination effect of the agglutinated sample through the test results. For example, the agglutination type of the agglutinated sample includes physiological agglutination and pathological agglutination. Here, a dilution factor of 512 is used as the standard for judging different agglutination types. After the deagglutination processing module 20 dilutes the agglutinated sample by less than 512 times (e.g., 256 times, 128 times, etc.), the control module 10 obtains the test information of the diluted agglutinated sample. When the test information indicates that the agglutination titer of the agglutinated sample diluted less than 512 times is high, the control module 10 determines that the agglutination type of the agglutinated sample is pathological agglutination. When the deagglutination processing module 20 dilutes the agglutinated sample by 512 times or more (e.g., 512 times, 1024 times, etc.), the control module 10 obtains the test information of the diluted agglutinated sample. When the test information indicates that the agglutination titer of the agglutinated sample diluted more than 512 times is low, the control module 10 determines that the agglutination type of the agglutinated sample is physiological agglutination.

[0108] For example, after the deagglutination processing module 20 performs a first dilution of the agglutinated sample at a ratio of less than 512 times (e.g., 256 times, 128 times, etc.), the control module 10 obtains the test information of the agglutinated sample after the first dilution. When the test information indicates that the agglutination titer of the agglutinated sample after the first dilution is high, the deagglutination processing module 20 performs a second dilution of the agglutinated sample at a ratio of 512 times or more (e.g., 512 times, 1024 times, etc.). The control module 10 obtains the test information of the agglutinated sample after the second dilution. When the test information indicates that the agglutination titer of the agglutinated sample after the second dilution is low, the control module 10 determines that the agglutination type of the agglutinated sample is physiological agglutination; otherwise, the agglutination type is pathological agglutination.

[0109] Understandably, the deagglomeration processing module 20 of this embodiment can obtain agglomeration type information of agglomerated samples by performing dilution processing on agglomerated samples at different dilution ratios, so that users can determine the agglomeration type of agglomerated samples, making it easier for users to perform different processing measures on agglomerated samples and improving the user experience.

[0110] Optionally, in this embodiment, the incubation position 230 includes at least one first incubation position 230 and a second incubation position 230, the first incubation position 230 being disposed in the incubation component and the second incubation position 230 being disposed in the second mixer 420.

[0111] Please see Figure 6 , Figure 6 This is a flowchart illustrating the fourth embodiment of the sample processing method provided in this application. Figure 6 As shown, in this embodiment, the control module 10 controls the deagglomeration processing module 20 to move the agglomerated sample to the incubation position 230 to perform incubation processing on the agglomerated sample. The steps include:

[0112] Step S41: When the sample is an agglutinated sample, the control module 10 obtains the usage status of the second incubation site 230.

[0113] Specifically, a detector may be provided at the second incubation site 230 to detect the usage status of the second incubation site 230. For example, the detector may be an optical coupler detector to detect whether there is agglutinated sample at the second incubation site 230.

[0114] Step S42: In response to the idle state, the control module 10 controls the deagglutination processing module 20 to move the agglutinated sample to the second incubation position 230.

[0115] When the second incubation position 230 is idle, the control module 10 controls the deagglutination processing module 20 to move the agglutinated sample to the second incubation position 230. Specifically, the second mixer 420 is used for mixing micro-volume blood tubes and is located on the side close to the first mixer 410, so that the first mixer 410 can transfer the micro-volume blood tube from the injection module to the second mixer 420. Therefore, when the second incubation position 230 is idle, the control module 10 prioritizes using the second incubation position 230 to incubate the agglutinated sample, which facilitates the gripping operation of the first mixer 410, reduces the transfer time of the agglutinated sample, and improves the efficiency of abnormal handling.

[0116] Step S43: In response to the usage state being incubation state, the control module 10 controls the deagglutination processing module 20 to move the agglutinated sample to the first incubation position 230.

[0117] When the second incubation position 230 is in the incubation state, that is, when there are other agglutinated samples undergoing incubation processing in the second incubation position 230, the control module 10 controls the deagglutination processing module 20 to move the agglutinated sample to the first incubation position 230 so as to perform incubation operation on the agglutinated sample through the first incubation position 230.

[0118] In this embodiment, the control module 10, in response to the second incubation position 230 being in an idle state, controls the deagglomeration processing module 20 to move the agglomerated sample to the second incubation position 230, so as to facilitate the grabbing operation of the first mixer 410, reduce the transfer time of the agglomerated sample, and improve the efficiency of abnormal processing.

[0119] Optionally, in other embodiments, the blood analyzer is provided with at least one first incubation position 230 and a second incubation position 230. The control module 10 can move the agglutinated sample alternately to the first incubation position 230 or the second incubation position 230 according to a preset sequence. For example, when the incubation component is provided with two first incubation positions 230, the control module 10 performs incubation processing on the agglutinated sample in the order of first incubation position 230, first incubation position 230, and second incubation position 230.

[0120] Optionally, please see Figure 7 , Figure 7 This is a flowchart illustrating the fifth embodiment of the sample processing method provided in this application. Figure 7 As shown, in this embodiment, step S12 includes the following steps:

[0121] Step S51: In response to the use state of the incubation position 230 being in the incubation state, the control module 10 unloads the agglutinated sample from the blood analyzer so that the agglutinated sample is incubated outside the blood analyzer.

[0122] Similarly, the incubation position 230 can be equipped with a detector to detect the usage status of the incubation position 230. For example, the detector can be an optical coupler detector to detect whether there is agglutinated sample in the incubation position 230. When there is agglutinated sample in the incubation position 230, that is, when the usage status of the incubation position 230 is in the incubation state, the control module 10 unloads the agglutinated sample from the blood analyzer and sends a prompt message to the visual interface so that the user can manually incubate the agglutinated sample after receiving the prompt message.

[0123] Step S52: The control module 10 controls the sample injection module to receive the sample and controls the sample injection module to scan the test tube containing the sample to obtain the sample identification information.

[0124] When unloading the agglutinated sample, the control module 10 can mark the identification code of the agglutinated sample. For example, the control module 10 can add the identification code of the agglutinated sample to the exception list. After the artificial incubation treatment of the agglutinated sample is completed, the user moves the test tube containing the agglutinated sample back to the injection module so that the injection module can scan the identification code of the test tube to obtain the identification information of the sample.

[0125] Step S53: The control module 10 determines whether the sample is an agglutinated sample after incubation based on the identification information.

[0126] After acquiring the identification information, the control module 10 determines whether the identification information includes a marker or whether the identification information is in the anomaly list, in order to determine whether the sample is an incubated agglutinated sample. Understandably, the identification information can be an image of an identification code.

[0127] Step S54: In response to the fact that the sample is an agglutinated sample after incubation, the control module 10 controls the deagglutination processing module 20 to dilute the agglutinated sample.

[0128] When the identification information includes a mark or the identification information is in the anomaly list, the control module 10 determines that the sample corresponding to the identification information is an agglutinated sample after incubation. At this time, the control module 10 controls the deagglutination processing module 20 to dilute the agglutinated sample.

[0129] When there are fewer incubation positions 230 in the blood analyzer, or when there are more agglutinated samples in the blood analyzer, multiple agglutinated samples may need to be incubated. Since incubation usually takes 5 to 60 minutes, which is time-consuming, in this embodiment, when the control module 10 responds to the use state of the incubation position 230 being in the incubation state, it can unload the agglutinated samples from the blood analyzer, so that the incubation process of the agglutinated samples can be carried out outside the blood analyzer, and the agglutinated samples do not need to wait, thus improving the efficiency of abnormal handling.

[0130] Further, before step S23 and / or before step S54, the sample processing method further includes: controlling the testing module to test the incubated agglutinated sample to obtain first test information of the agglutinated sample. Step S13 includes: the control module 10 controlling the testing module to detect the diluted agglutinated sample to obtain second test information of the agglutinated sample; the control module 10 determining whether the agglutination titer of the diluted agglutinated sample is within a preset range based on the first test information and the second test information, thereby obtaining the detection result of the agglutinated sample.

[0131] After obtaining the first test information and the second test information, step S14 further includes: the control module 10, in response to the first test information and the second test information not meeting the first preset condition, takes the second test information or the first test information as the detection result; the control module 10, in response to the first test information and the second test information meeting the first preset condition, generates a warning message.

[0132] The agglutinated sample is a red blood cell agglutination sample, and the first and second test information includes at least RBC, MCHC, and MCV. 、 At least one of the HCT and MCH parameters. For example, the control module 10 determines whether the first agglutination titer of the incubated agglutinated sample is too high based on the first test information, and determines whether the second agglutination titer of the diluted agglutinated sample is too high based on the second test information. Understandably, the first preset condition is used to determine whether hemagglutination has occurred in the incubated agglutinated sample and the diluted agglutinated sample based on the first test information and the second test information. The first preset condition can be one of the determination methods described in the above embodiments or a combination of multiple determination methods.

[0133] When the first and second test information do not meet the first preset condition, i.e., both the first and second agglutination titers are low, the degree of blood cell agglutination in the incubated and diluted agglutinated samples is not high or no blood cell agglutination occurs. The control module 10 further obtains a second ratio of the RBC parameters of the diluted and incubated agglutinated samples to select either the first or second test information as the detection result of the agglutinated sample based on this second ratio. When the second ratio of the diluted RBC to the incubated RBC is greater than a fourth preset value, the dilution treatment has a certain deagglutination effect, and the control module 10 uses the second test information as the detection result of the agglutinated sample. When the second ratio of the diluted RBC to the incubated RBC is less than or equal to the fourth preset value, the deagglutination effect of the dilution treatment is poor, and the control module 10 uses the first test information as the detection result of the agglutinated sample. The fourth preset value can be set according to the sensitivity of the blood analyzer's agglutination judgment; for example, the fourth preset value can be set to 1.1 or 1.2, without specific limitation.

[0134] When the first test information and the second test information meet the first preset condition, that is, both the first agglutination titer and the second agglutination titer are high, or the first agglutination titer or the second agglutination titer is high, at least one of the agglutinated samples after incubation and the diluted agglutinated sample has a high degree of blood cell agglutination, which indicates that the deagglutination processing module 20 has an insignificant effect. At this time, the control module 10 generates a warning message.

[0135] Furthermore, after the control module 10 generates a warning message, the warning message can be displayed on the visual interface of the blood analyzer for the user to view. In an optional embodiment, the warning message may include multiple selection instructions to process the agglutinated sample in response to the user's selection of these instructions. For example, the selection instructions may include a first selection instruction to instruct the control module 10 to perform a secondary deagglutination process on the agglutinated sample and a second selection instruction to instruct the control module 10 to remove the agglutinated sample from the blood analyzer, etc., without specific limitations.

[0136] In response to a warning message, the control module 10 controls the deagglutination processing module 20 to perform a secondary deagglutination process on the agglutinated sample. The secondary deagglutination process can be any of the deagglutination schemes described above. For example, in response to a warning message, the control module 10 performs a secondary incubation process on the agglutinated sample to increase the incubation time of the agglutinated sample, and / or performs a second dilution process on the agglutinated sample, which is greater than the first dilution process, so that the agglutinated sample further increases the intercellular spacing at the second dilution, thereby increasing the effect of the deagglutination process.

[0137] In an optional implementation, the blood analyzer can select different secondary dilution schemes based on the conditions of the first and second agglutination titers. For example, when the first agglutination titer of the incubated agglutinated sample is high and the second agglutination titer of the diluted agglutinated sample is low, the control module 10 can further obtain a second ratio of the RBC parameters of the diluted agglutinated sample and the incubated agglutinated sample. When the second ratio is greater than a fourth preset value, it indicates that the dilution treatment has a certain deagglutination effect. In response to a warning message, the control module 10 can control the deagglutination treatment module 20 to perform a second dilution treatment on the agglutinated sample at a second dilution factor. At the first dilution factor, the intercellular spacing of the agglutinated sample is further increased. After the second dilution factor is completed, the test module 30 is controlled to test the agglutinated sample, and the test result is used as the final test result. If the first agglutination titer of the incubated agglutinated sample is low and the second agglutination titer of the diluted agglutinated sample is high, it indicates that the dilution factor selected when diluting the incubated agglutinated sample is too large, resulting in an increase in the agglutination titer of the agglutinated sample. At this time, the control module 10 can respond to the warning information and control the deagglutination processing module 20 to perform a third dilution factor on the agglutinated sample, which is less than the first dilution factor.

[0138] Optionally, the test information includes at least one of the following: blood cell count, blood cell volume, hemoglobin, and hematocrit of the agglutinated sample. For example, when the agglutinated sample is a red blood cell agglutination sample, the test information of the agglutinated sample includes at least one of the following: mean corpuscular hemoglobin concentration (MCHC), mean corpuscular volume (MCV), hematocrit (HCT), red blood cell count (RBC), and mean corpuscular hemoglobin content (MCH).

[0139] Optionally, after the step of the control module 10 controlling the sample addition module 40 to receive the sample, the sample processing method further includes: the control module 10 controlling the first mixer 410 to perform mixing processing on the sample in the second mixing mode; and the control module 10 controlling the sample needle 430 to perform sampling operation on the mixed sample so that the test module 30 can detect the sample.

[0140] Optionally, step S14 includes: the control module 10 controls the first mixer 410 to acquire the agglomerated sample and performs a mixing process on the agglomerated sample in a first mixing mode, wherein the mixing intensity of the first mixing mode is less than the mixing intensity of the second mixing mode; the control module 10 controls the sample needle 430 to perform a sampling operation on the mixed agglomerated sample and controls the test module 30 to detect the sampled agglomerated sample to obtain the detection result of the agglomerated sample.

[0141] This application also proposes a sample detection method for testing samples from a blood analyzer, determining whether the sample is an agglutinated sample based on the sample information, and obtaining the corresponding test result based on the determination result. Please see [link to relevant documentation]. Figure 8 , Figure 8 This is a flowchart illustrating the first embodiment of the sample detection method provided in this application. Figure 8 As shown, the sample detection method in this embodiment includes the following steps:

[0142] Step S61: Control module 10 controls test module 30 to test the sample in order to obtain sample information.

[0143] Specifically, the sample information is related to the sample object and the detection method of the test module 30. The test module 30 includes multiple sample testing components. For example, the test module 30 may include a first test component for impedance detection and a second test component for specific protein detection. In one embodiment, the sample information includes parameter information. The control module 10 controls the first test component to detect the sample to obtain the sample's red blood cell parameter information, including MCHC, MCV, HCT, RBC, and MCH, etc. Alternatively, the control module 10 controls the first test component to perform red blood cell detection or platelet detection on the sample to obtain histogram information. In another embodiment, the control module 10 controls the second test component to detect the sample to obtain statistical information such as a statistical scatter plot of blood cells. In yet another embodiment, the sample information includes agglutination image information. The test module 30 includes an image detection component that performs image detection on the sample to obtain agglutination image information.

[0144] For example, when the sample is a white blood cell sample, the sample information includes histogram information of the white blood cell channel. The histogram information may include pulse width information and pulse peak number information, etc. The control module determines whether the white blood cell agglutination sample is an agglutination sample by obtaining the pulse width information and pulse peak number information. When the sample is a PLT sample, the sample information includes PLT count information, MPV (mean platelet volume) information, etc., and / or, the sample information may also include statistical information such as platelet statistical scatter plot.

[0145] Step S62: The control module 10 determines whether the sample is an agglutinated sample based on the sample information.

[0146] Specifically, after acquiring sample information such as red blood cell parameter information, histogram information, statistical information or agglutination image information, the control module 10 determines whether the sample is an agglutinated sample based on the sample information.

[0147] Step S63: The control module 10 obtains the detection result of the sample based on the judgment result of the sample.

[0148] The control module 10 obtains the test result of the sample based on the judgment result of the sample. The judgment result includes at least two categories: the sample is a normal sample and the sample is an agglutinated sample. When the sample is a normal sample, the blood analyzer does not need to perform abnormal processing on the normal sample. When the sample is an agglutinated sample, the blood analyzer performs abnormal processing on the agglutinated sample.

[0149] In this embodiment, the sample detection method can detect the sample through the test module 30 to obtain sample information, and the control module 10 can make anomaly judgment on the sample based on the sample information. There is no need for manual identification of agglutinated samples, which reduces labor costs and improves the analysis efficiency of the blood analyzer.

[0150] Optionally, step S63 further includes the following step: in response to the sample being an agglutinated sample, the control module 10 controls the deagglutination processing module 20 to perform deagglutination processing on the agglutinated sample. The deagglutination processing includes deagglutination processing and test channel switching, and the deagglutination processing includes incubation processing and / or dilution processing.

[0151] For example, in one embodiment, the deagglutination process involves the deagglutination processing module 20 incubating the agglutinated sample; in another embodiment, the deagglutination process involves the deagglutination processing module 20 incubating the agglutinated sample and then diluting the incubated agglutinated sample; in yet another embodiment, when all the incubation positions 230 of the blood analyzer are in the incubation process, the user manually incubates the agglutinated sample outside the blood analyzer, the blood analyzer receives the incubated agglutinated sample, and the deagglutination processing module 20 dilutes the agglutinated sample. According to the sample information or user instructions, the control module 10 can control the deagglutination processing module 20 to perform different deagglutination processing procedures on the agglutinated sample.

[0152] After the deagglomeration processing module 20 performs deagglomeration processing on the agglomerated sample, the control module 10 controls the testing module 30 to test the processed agglomerated sample to obtain test information of the agglomerated sample, and generates the test result of the agglomerated sample based on the test information. The specific method for obtaining the test result in step S74 is similar to the method described above, and will not be repeated here.

[0153] In this embodiment, the control module 10 controls the testing module 30 to test the sample to obtain sample information. The control module 10 determines whether the sample is an agglutinated sample based on the sample information. If the sample is an agglutinated sample, the control module 10 controls the deagglutination processing module 20 to perform deagglutination processing on the agglutinated sample, and controls the testing module 30 to test the processed agglutinated sample to obtain test information. The control module 10 generates the test result of the agglutinated sample based on the test information. This sample detection method can determine anomalies in the sample based on sample information and perform deagglutination processing on the agglutinated sample based on the anomaly determination result, eliminating the need for manual processing of agglutinated samples, reducing sample processing costs, and improving the analytical efficiency of the blood analyzer.

[0154] Optionally, step S62 includes: the control module 10 determines that the sample is an agglutinated sample in response to the sample information not meeting the first preset condition.

[0155] Specifically, in one embodiment, when the sample information includes parameter information, for example, the parameter information is red blood cell parameter information. When the red blood cell parameter includes MCHC, the sample can be determined to be an agglutinated sample by judging whether MCHC is greater than a first preset value, the first preset value including but not limited to 360 mg / L or 380 mg / L; when the red blood cell parameter includes MCV, the sample can be determined to be an agglutinated sample by judging whether MCV is too high; when the red blood cell parameter includes HCT, the sample can be determined to be an agglutinated sample by judging whether HCT is too low; when the red blood cell parameter includes MCH, the sample can be determined to be an agglutinated sample by judging whether MCH is greater than a second preset value, the second preset value including but not limited to 33 pg; when the red blood cell parameter includes RBC and HGB, the condition for determining an agglutinated sample is whether a first ratio of HGB to RBC is greater than a third preset value, the third preset value including but not limited to 30.

[0156] When the parameter information is platelet parameter information, including PLT and MPV, the control module can determine whether the sample is an agglutination sample by judging whether PLT is too low and MPV is too high. When PLT is too low and MPV is too high, the control module 10 determines that the sample is an agglutination sample.

[0157] In another embodiment, when the sample information includes histogram information for red blood cell detection or platelet detection, the histogram is usually plotted with cell volume on the horizontal axis and cell number on the vertical axis. The symmetry of the histogram waveform can be used to determine whether the sample is an agglutinated sample.

[0158] In another embodiment, when the sample information includes a statistical scatter plot for cell classification, the scatter plot typically uses lateral fluorescence signal as the abscissa and forward scatter signal as the ordinate. By judging the aggregation shape and intensity distribution of blood cells in the statistical scatter plot, agglutinated samples can be identified. For example, when the sample is a platelet sample, the control module 10 can determine whether the sample is an agglutinated sample by judging whether there are particles with obviously high fluorescence intensity but low forward scatter intensity in the forward scatter and fluorescence of the WNR scatter plot.

[0159] Understandably, the above-mentioned various judgment methods can be combined arbitrarily. For example, MCV and HCT parameters can be used as the basis for judging agglutinated samples; or, the first ratio of HGB to RBC, MCH, and MCHC parameters can be used as the basis for judging agglutinated samples; or, statistical scatter plots, histograms, and red blood cell parameter information can be combined as the basis for judging agglutinated samples. Depending on the usage scenario, the detection sequence of different test items by the blood analyzer, and the sensitivity of agglutination judgment, different judgment methods can be selected to determine agglutinated samples. Here, no specific limitation is made on the first preset condition.

[0160] Optionally, step S63 includes the following steps: the control module 10 obtains the degree of agglomeration of the agglomerated sample based on the sample information; the control module 10 controls the deagglomeration processing module 20 to perform deagglomeration processing on the agglomerated sample based on the degree of agglomeration.

[0161] Specifically, after determining that a sample is an agglutinated sample based on the sample information, the control module 10 obtains the degree of agglutination of the agglutinated sample and controls the deagglutination processing module 20 to perform corresponding deagglutination processing on the agglutinated sample according to the degree of agglutination. Understandably, the deagglutination processing module 20 includes multiple deagglutination processing schemes, each corresponding to the degree of agglutination of the agglutinated sample. When the degree of agglutination of the agglutinated sample is low, the deagglutination processing module 20 selects a deagglutination processing scheme with a lower processing degree. For example, the deagglutination processing schemes include incubation treatment and dilution treatment. A lower deagglutination processing scheme could be an incubation treatment scheme with a shorter incubation time and / or a dilution treatment scheme with a lower dilution factor, etc.

[0162] Further, please see Figure 9 , Figure 9 This is a flowchart illustrating the second embodiment of the sample detection method provided in this application. Figure 9 As shown, step S63 includes the following steps:

[0163] Step S71: The control module 10 determines whether the sample information meets the second preset condition, and the range of the second preset condition is smaller than the range of the first preset condition.

[0164] In this embodiment, before determining whether the sample information meets the second preset condition, the control module 10 performs a first preset condition judgment on the sample information. That is, after the sample information meets the first preset condition, the control module 10 performs a second preset condition judgment on the sample.

[0165] The second preset condition is similar to the first preset condition in the above embodiment. For example, when the control module 10 determines whether the sample is an agglutinated sample based on whether the MCHC parameter is greater than the first preset value, the control module 10 can determine whether the sample information meets the second preset condition based on whether the MCHC is greater than the fifth preset value. The fifth preset value must be greater than the first preset value. For example, the first preset value is 380 mg / L, the fifth preset value is 400 mg / L, the range of the first preset condition is (380, ∞), and the range of the second preset condition is (400, ∞). The limitation range of the second preset condition is less than the limitation range of the first preset condition.

[0166] Step S72: When the sample information does not meet the second preset condition, the control module 10 determines that the agglomerated sample is at the first agglomeration level.

[0167] When the sample information does not meet the second preset condition, for example, when judging the second preset condition based on the MCHC parameter, if the MCHC parameter is greater than 380 mg / L and less than or equal to 400 mg / L, it means that the sample information does not meet the second preset condition, the degree of red blood cell agglutination of the agglutinated sample is low, and the control module 10 determines that the agglutinated sample is at the first agglutination level.

[0168] Step S73: When the sample information meets the second preset condition, the control module 10 determines that the agglomerated sample is at the second agglomeration level.

[0169] When the sample information meets the second preset condition, for example, when judging the second preset condition based on the MCHC parameter, if the MCHC parameter is greater than 400 mg / L, it means that the sample information meets the second preset condition, the degree of red blood cell agglutination of the agglutinated sample is high, and the control module 10 determines that the agglutinated sample is at the second agglutination level.

[0170] Understandably, depending on the sample information selected under the first preset condition, there are multiple ways to determine whether the sample information meets the second preset condition. For example, when the control module 10 determines whether a sample is an agglomerated sample based on the waveform symmetry of the histogram information, the degree of agglomeration of the agglomerated sample can be determined by judging the degree of waveform symmetry of the histogram information. Here, no specific limitation is made on the second preset condition.

[0171] In this embodiment of the application, the sample detection method can obtain the degree of agglutination of the agglutinated sample based on the sample information, so that the control module 10 can execute the corresponding abnormal handling scheme according to different agglutination degrees, so as to avoid unnecessary deagglutination processing for samples with low agglutination degree, reduce the time spent on abnormal handling, and improve the analysis efficiency of the blood analyzer.

[0172] In an optional embodiment, the step of the deagglomeration processing module 20 performing deagglomeration processing on the agglomerated sample according to the degree of agglomeration includes: in response to the agglomerated sample being at a first degree of agglomeration, the control module 10 controls the deagglomeration processing module 20 to perform incubation processing on the agglomerated sample at a first preset temperature; in response to the agglomerated sample being at a second degree of agglomeration, the control module 10 controls the deagglomeration processing module 20 to perform incubation processing on the agglomerated sample, and controls the deagglomeration processing module 20 to perform dilution processing on the agglomerated sample after incubation processing by a first preset factor.

[0173] Specifically, when the agglutinated sample is at the second agglutination level, the deagglutination process includes the following steps: the control module 10 controls the deagglutination process module 20 to incubate the agglutinated sample at a first preset temperature; the control module 10 adds the incubated agglutinated sample to the dilution component; the control module 10 adds diluent to the dilution component to dilute the agglutinated sample by a first preset factor, so that the agglutinated sample deagglutinates at the first preset factor of dilution.

[0174] Furthermore, when the deagglomeration processing module 20 processes agglomerated samples, the diluent needs to be heated to a second preset temperature before being added to the dilution component.

[0175] In another optional embodiment, after step S83, the sample detection method further includes: the control module 10 determining whether the sample information meets a third preset condition, the range of the third preset condition being smaller than the range of the second preset condition; when the sample information meets the third preset condition, the control module 10 determining that the agglomerated sample is at a third agglomeration degree.

[0176] Similarly, the third preset condition is similar to the second and first preset conditions mentioned above. When the control module 10 determines whether the sample information meets the third preset condition, the sample information meets the second and first preset conditions. For example, when the control module 10 determines whether the sample is an agglutinated sample based on whether the MCHC parameter is greater than the first preset value, the control module 10 can determine whether the sample information meets the third preset condition based on whether the MCHC is greater than the sixth preset value. For example, the first preset value is 380 mg / L, the fifth preset value is 400 mg / L, and the sixth preset value is 420 mg / L. The range of the first preset condition is (380, ∞), the range of the second preset condition is (400, ∞), and the range of the third preset condition is (420, ∞). The limitation range of the third preset condition is smaller than the limitation range of the second preset condition.

[0177] When the sample information meets the third preset condition, for example, when the MCHC parameter of the sample information is greater than 420 mg / L, it means that the sample information meets the third preset condition, the degree of red blood cell agglutination of the agglutinated sample is high, and the control module 10 determines that the agglutinated sample is at the third agglutination level.

[0178] The steps of the deagglomeration processing module 20 in performing deagglomeration processing on agglomerated samples according to the degree of agglomeration include: in response to the agglomerated sample being at a first degree of agglomeration, the control module 10 controls the deagglomeration processing module 20 to perform incubation treatment at a first preset temperature on the agglomerated sample; in response to the agglomerated sample being at a second degree of agglomeration, the control module 10 controls the deagglomeration processing module 20 to perform incubation treatment on the agglomerated sample and controls the deagglomeration processing module 20 to perform dilution treatment at a first preset factor on the agglomerated sample after incubation treatment; in response to the agglomerated sample being at a third degree of agglomeration, the control module 10 controls the deagglomeration processing module 20 to perform dilution treatment at a second preset factor, wherein the second preset factor is greater than the first preset factor.

[0179] Understandably, the higher the dilution factor, the better the deagglutination effect of the blood cell agglutination sample. When the agglutinated sample is at the third agglutination level, the second preset factor is greater than or equal to 500 times. For example, the first preset factor is 250 times and the second preset factor is 500 times; or the first preset factor is 500 times and the second preset factor is 1000 times.

[0180] In other embodiments, the step of the deagglomeration processing module 20 performing deagglomeration processing on the agglomerated sample according to the degree of agglomeration may further include: in response to the agglomerated sample being at a first degree of agglomeration, the control module 10 controls the deagglomeration processing module 20 to perform a first preset temperature incubation treatment on the agglomerated sample so that the agglomerated sample deagglomerates within a first preset time; in response to the agglomerated sample being at a second degree of agglomeration, the control module 10 controls the deagglomeration processing module 20 to perform a first preset temperature incubation treatment on the agglomerated sample so that the agglomerated sample deagglomerates within a second preset time, wherein the second preset time is longer than the first preset time.

[0181] Specifically, when the deagglomeration processing module 20 performs an incubation process, the control module 10 can control the deagglomeration processing module 20 to incubate the agglomerated sample for different durations depending on the degree of agglomeration. The second preset time and the first preset time are both within the range of 5 to 60 minutes, with the second preset time being longer than the first preset time. For example, when the agglomerated sample is at the first degree of agglomeration, the control module 10 controls the deagglomeration processing module 20 to incubate the agglomerated sample for the first preset time, which can be 10 minutes; when the agglomerated sample is at the second degree of agglomeration, the control module 10 controls the deagglomeration processing module 20 to incubate the agglomerated sample for the second preset time, which can be 30 minutes.

[0182] Optionally, the sample information includes parameter information, which includes at least one of the sample's red blood cell count, red blood cell volume, hemoglobin, and hematocrit information.

[0183] Optionally, the sample information includes agglomeration image information. In this embodiment, step S62 includes the following steps: the control module 10 acquires the agglomeration image information and matches the agglomeration image information with preset feature information; when the matching degree between the agglomeration image information and the preset feature information is greater than a preset threshold, the control module 10 determines that the sample is an agglomeration sample.

[0184] Specifically, when the sample is a blood cell agglutination sample, the sample will exhibit characteristics of blood cell agglutination, such as a sand-like or granular appearance. In this embodiment, the control module 10 can determine whether the sample is an agglutinated sample based on the agglutination image information. The preset feature information refers to the characteristic information of blood cell agglutination samples; for example, the preset feature information could be the sand-like characteristic information of blood cell agglutination samples. The control module 10 determines the agglutinated sample based on the degree of matching between the agglutination image information and the preset feature information.

[0185] The control module 10 can utilize various visual correlation algorithms to detect or identify relevant features, states, and attributes of the aggregated image information, thereby obtaining the matching degree between the aggregated image information and preset feature information. Visual correlation algorithms may involve visual localization, SLAM, background segmentation, object keypoint extraction and tracking, etc. The control module 10 can use a convolutional neural network to detect or identify relevant features, states, and attributes of the target object. For example, a convolutional neural network is a network model obtained by training a model based on a deep learning framework.

[0186] Furthermore, when obtaining the agglomeration degree of agglomerated samples based on sample information, the agglomeration degree of agglomerated samples can be obtained by comparing the matching degree between agglomerated image information and preset feature information with multiple preset thresholds.

[0187] Please see Figure 10 , Figure 10 This is a schematic diagram of the third embodiment of the blood analyzer provided in this application. Figure 10 As shown, the blood analyzer 100 includes a processor 101 and a memory 102 connected to the processor 101. The memory 102 stores program data, and the processor 101 retrieves the program data stored in the memory 102 to execute all the methods described above.

[0188] Optionally, in one embodiment, the processor 101 is used to execute program data to implement the following method: the control module 10 acquires sample information of the sample and determines whether the sample is an agglomerated sample based on the sample information; when the sample is an agglomerated sample, the control module 10 controls the deagglomeration processing module 20 to perform deagglomeration processing on the agglomerated sample; the control module 10 controls the testing module 30 to detect the processed agglomerated sample to obtain test information of the agglomerated sample; the control module 10 generates the detection result of the agglomerated sample based on the test information.

[0189] Optionally, in another embodiment, the processor 101 is used to execute program data to implement the following method: the control module 10 controls the test module 30 to detect the sample to obtain sample information; the control module 10 determines whether the sample is an agglutinated sample based on the sample information; the control module 10 obtains the detection result of the sample based on the determination result of the sample.

[0190] The processor 101 can also be referred to as a CPU (Central Processing Unit). The processor 101 may be an electronic chip with signal processing capabilities. The processor 101 can also be a general-purpose processor, a digital signal processor (DSP), an application-specific integrated circuit (ASIC), a field-programmable gate array (FPGA), or other programmable logic devices, discrete gate or transistor logic devices, or discrete hardware components. A general-purpose processor can be a microprocessor or any conventional processor.

[0191] The memory 102 can be a memory module, TF card, etc., and can store all the information in the blood analyzer 100, including the raw input data, computer program, intermediate running results, and final running results. It stores and retrieves information according to the location specified by the processor 101. With the memory 102, the blood analyzer 100 has a memory function and can ensure normal operation. The memory 102 of the blood analyzer 100 can be classified according to its purpose as main memory (RAM) and auxiliary memory (external memory), or it can be classified as external memory and internal memory. External memory is usually magnetic media or optical discs, which can store information for a long time. RAM refers to the storage component on the motherboard, used to store currently executing data and programs, but it is only used for temporary storage of programs and data; the data will be lost when the power is turned off.

[0192] Please see Figure 11 , Figure 11 This is a schematic diagram of the structure of an embodiment of the computer-readable storage medium provided in this application. Figure 11 As shown, the computer-readable storage medium 110 stores program instructions 111 capable of implementing all of the above methods.

[0193] If the integrated units of the various functional units in the various embodiments of this application are implemented as software functional units and sold or used as independent products, they can be stored in the computer-readable storage medium 110. Based on this understanding, the technical solution of this application, in essence, or the part that contributes to the prior art, or all or part of the technical solution, can be embodied in the form of a software product. The computer-readable storage medium 110 includes several instructions in a program instruction 111 to cause a computer device (which may be a personal computer, system server, or network device, etc.), an electronic device (e.g., MP3, MP4, etc., or a mobile terminal such as a mobile phone, tablet, or wearable device, or a desktop computer, etc.) or a processor to execute all or part of the steps of the methods of the various embodiments of this application.

[0194] Those skilled in the art will understand that embodiments of this application can be provided as methods, systems, or computer program products. Therefore, this application can take the form of a completely hardware embodiment, a completely software embodiment, or an embodiment combining software and hardware aspects. Furthermore, this application can take the form of a computer program product embodied on one or more computer-readable storage media 110 (including but not limited to disk storage, CD-ROM, optical storage, etc.) containing computer-usable program code.

[0195] This application is described with reference to flowchart illustrations and / or block diagrams of methods, apparatus (systems), and computer program products according to embodiments of this application. It will be understood that each block of the flowchart illustrations and / or block diagrams, and combinations of blocks in the flowchart illustrations and / or block diagrams, can be implemented by computer-readable storage medium 110. These computer-readable storage media 110 can be provided to a processor of a general-purpose computer, special-purpose computer, embedded processor, or other programmable data processing apparatus to produce a machine, such that program instructions 111, executable by the processor of the computer or other programmable data processing apparatus, generate instructions for implementing the flowchart illustrations and / or block diagrams. Figure 1 One or more processes and / or boxes Figure 1 A device that provides the functions specified in one or more boxes.

[0196] These computer-readable storage media 110 may also be stored in a computer-readable memory that can direct a computer or other programmable data processing device to operate in a particular manner, such that program instructions 111 stored in the computer-readable storage medium 110 produce an article of manufacture including instruction means, which are implemented in a process Figure 1 One or more processes and / or boxes Figure 1 The function specified in one or more boxes.

[0197] These computer-readable storage media 110 may also be loaded onto a computer or other programmable data processing apparatus to cause a series of operational steps to be performed on the computer or other programmable apparatus to produce a computer-implemented process, thereby providing program instructions 111 that execute on the computer or other programmable apparatus for implementing the process. Figure 1 One or more processes and / or boxes Figure 1 The steps of the function specified in one or more boxes.

[0198] Any process or method described in the flowchart or otherwise herein can be understood as representing a module, segment, or portion of code comprising one or more executable instructions for implementing a particular logical function or process, and the scope of the preferred embodiments of this application includes additional implementations in which functions may be performed not in the order shown or discussed, including substantially simultaneously or in reverse order depending on the function involved, as will be understood by those skilled in the art to which embodiments of this application pertain.

[0199] The logic and / or steps represented in the flowchart or otherwise described herein, for example, can be considered as a sequenced list of executable instructions for implementing logical functions, and can be embodied in any computer-readable medium for use by, or in conjunction with, an instruction execution system, apparatus or device (which may be a personal computer, server, network device or other system that can fetch and execute instructions from, an instruction execution system, apparatus or device).

[0200] The above description is merely an embodiment of this application and does not limit the patent scope of this application. Any equivalent structural or procedural transformations made using the content of this application's specification and drawings, or direct or indirect applications in other related technical fields, are similarly included within the patent protection scope of this application.

Claims

1. A blood analyzer, characterized in that, include: The testing module is used to test the sample to obtain sample information, which includes agglutination image information and / or parameter information. The control module is used to determine whether the sample is an agglutinated sample based on the sample information, and to obtain the detection result of the sample based on the determination result of the sample; The testing module includes an image detection component, which is used to perform image detection on the sample to obtain the agglomeration image information. The control module is used to determine that the sample is the agglomeration sample when the matching degree between the agglomeration image information and the preset feature information is greater than a preset threshold. The preset feature information includes sample layering features and / or sample surface features. The control module is used to obtain color value change information or grayscale change information of the sample in the test tube extension direction according to the agglomeration image information, so as to obtain the matching degree between the sample layering features and the agglomeration image information according to the color value change information or the grayscale change information, and / or the control module is used to identify the gravel-like or flocculent features of the agglomeration image information to obtain the matching degree between the sample surface features and the agglomeration image information; The blood analyzer further includes a deagglutination processing module and at least one incubation position, the incubation position being used to place agglutinated samples, and the deagglutination processing module being used to incubate the agglutinated samples located in the incubation position; the deagglutination processing module includes a dilution component, the dilution component being used to dilute the agglutinated samples by a preset factor. The control module is further configured to obtain the agglutination degree of the sample based on the sample information, wherein the agglutination degree includes at least a first agglutination degree and a second agglutination degree, and the agglutination titer of the second agglutination degree is greater than that of the first agglutination degree; the deagglutination processing module is configured to perform the incubation treatment on the agglutinated sample of the first agglutination degree, and is also configured to perform the incubation treatment and the dilution treatment on the agglutinated sample of the second agglutination degree. The testing module is used to test the processed sample to obtain test information of the sample; the control module is also used to generate the test result of the sample based on the test information.

2. The blood analyzer according to claim 1, characterized in that, The control module is used to determine that the sample is an agglutinated sample when the sample information does not meet the first preset condition.

3. The blood analyzer according to claim 1, characterized in that, The parameter information includes at least one of the red blood cell parameter information, platelet parameter information, and white blood cell parameter information of the sample, and the control module is used to determine whether the parameter information meets the first preset condition.

4. The blood analyzer according to claim 1, characterized in that, The sample information includes agglutination image information and parameter information. The control module is used to determine that the sample is an agglutinated sample when neither the agglutination image information nor the parameter information meets the first preset condition.

5. A sample detection method, characterized in that, Applied to the blood analyzer as described in any one of claims 1-4, comprising: The control module controls the test module to detect the sample in order to obtain sample information, which includes agglutination image information and / or parameter information. The control module determines whether the sample is an agglutinated sample based on the sample information. The control module obtains the detection result of the sample based on the judgment result of the sample.

6. The sample detection method according to claim 5, characterized in that, The step of the control module determining whether the sample is an agglutinated sample based on the sample information includes: The control module determines that the sample is an agglutinated sample in response to the sample information not meeting the first preset condition.

7. The sample detection method according to claim 6, characterized in that, The step of the control module obtaining the detection result of the sample based on the judgment result of the sample includes: In response to the fact that the sample is an agglutinated sample, the control module controls the deagglutination processing module to perform deagglutination processing on the sample; The control module controls the testing module to test the processed sample in order to obtain the test results of the sample.

8. The sample detection method according to claim 7, characterized in that, The step of the control module controlling the deagglomeration processing module to perform deagglomeration processing on the sample in response to the sample being an agglomerated sample includes: The control module obtains the degree of agglomeration of the agglomerated sample based on the sample information; The control module controls the deagglomeration processing module to perform deagglomeration processing on the agglomerated sample according to the degree of agglomeration.

9. The sample detection method according to claim 8, characterized in that, The step of the control module obtaining the agglutination degree of the agglutinated sample based on the sample information includes: The control module determines whether the sample information meets a second preset condition, and the range of the second preset condition is smaller than the range of the first preset condition. When the sample information does not meet the second preset condition, the control module determines that the agglomerated sample is at the first agglomeration level; When the sample information meets the second preset condition, the control module determines that the agglomerated sample is at the second agglomeration level.

10. The sample detection method according to claim 9, characterized in that, The control module controls the deagglomeration processing module according to the degree of agglomeration, so that the deagglomeration processing module performs deagglomeration processing on the agglomerated sample, including: In response to the agglutinated sample being at the first agglutination level, the control module controls the deagglutination processing module to perform an incubation treatment at a first preset temperature on the agglutinated sample. In response to the agglutinated sample being at the second agglutination level, the control module controls the deagglutination processing module to perform the incubation treatment on the agglutinated sample, and controls the deagglutination processing module to perform a first preset dilution treatment on the agglutinated sample after the incubation treatment.

11. The sample detection method according to claim 10, characterized in that, The step of the control module obtaining the agglutination degree of the agglutinated sample based on the sample information includes: The control module determines whether the sample information meets a third preset condition, and the range of the third preset condition is smaller than the range of the second preset condition. When the sample information meets the third preset condition, the control module determines that the agglomerated sample is at the third agglomeration level; The control module controls the deagglomeration processing module to perform deagglomeration processing on the agglomerated sample according to the degree of agglomeration, including: In response to the agglomerated sample being at the third agglomeration level, the control module controls the deagglomeration processing module to dilute the agglomerated sample by a second preset factor, the second preset factor being greater than the first preset factor.

12. The sample detection method according to claim 9, characterized in that, The control module controls the deagglomeration processing module according to the degree of agglomeration, so that the deagglomeration processing module performs deagglomeration processing on the agglomerated sample, including: In response to the agglomerated sample being at the first agglomeration level, the control module controls the deagglomeration processing module to perform an incubation treatment at a first preset temperature on the agglomerated sample, so that the agglomerated sample deagglomerates within a first preset time. In response to the agglomerated sample being at the second agglomeration level, the control module controls the deagglomeration processing module to perform incubation treatment at the first preset temperature on the agglomerated sample, so that the agglomerated sample deagglomerates within a second preset time, the second preset time being longer than the first preset time.

13. The sample detection method according to claim 6, characterized in that, The parameter information includes at least one of the following: red blood cell count, red blood cell volume, hemoglobin, and hematocrit of the sample.

14. The sample detection method according to claim 6, characterized in that, The step of the control module determining whether the sample is an agglutinated sample based on the sample information includes: The control module acquires the agglomeration image information and matches the agglomeration image information with preset feature information; When the matching degree between the agglomerated image information and the preset feature information is greater than a preset threshold, the control module determines that the sample is the agglomerated sample.

Images